Effe-PLUS platform is an engineering technology primarily designed to solve problems for health supplement ingredients, such as undesirable flavors, poor stability, low bioavailability, inability to disperse in cold water, etc., offering differentiated nutritional health solutions to create competitive advantages for customers. Effe-PLUS platform mainly includes LipoAvail® Liposomal Technology, EncapCirc™ Microencapsulation Technology, and CelleSperse™ Micelles Technology. According to their respective characteristics, these technologies can be applied to different active ingredients, such as vitamins, minerals, plant extracts, and various other active ingredients.

Uthever: 
Uthever® is the world's first clinically-proven NMN (β-Nicotinamide Mononucleotide) brand. Uthever® is recognized globally, available in various markets, and often favored by consumers looking for premium NMN supplements. NMN is a derivative of vitamin B3, which plays a crucial role in human cell functions. Research shows that NMN is a bioactive compound that can boost cellular NAD+ levels. As we age, NAD+ levels in the body decline. Supplementing NAD+ can effectively slow down aging and improve the prevention and management of age-related diseases.

UthPeak:
UthPeak® went through the world's first, largest, and longest human clinical trial on reduced NMN (NMNH). NMNH is the reduced form of Nicotinamide Mononucleotide (NMN). Both NMN and reduced NMN (also known as NMNH) are NAD+ precursors. Research has shown that NMNH is a more effective NAD+ enhancer than market-available NAD+ precursors.

LipoAvail:
LipoAvail® is EffePharm's advanced liposomal technology to optimize nutrient delivery. The phospholipid bilayer of LipoAvail® closely mimics the structure of intestinal cell membranes, enhancing absorption and significantly improving bioavailability compared to conventional formulations.